HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention.
AuthorsTaylor, Malcolm B
Harrison, Christine J
Eden, Tim O B
Birch, Jillian M
Greaves, Mel F
AffiliationCancer Immunogenetics Laboratory, St Mary's Hospital, University of Manchester, Manchester, M13 0JH, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractMost childhood B cell precursor (BCP) acute lymphoblastic leukaemia (ALL) cases carry the reciprocal translocation t(12;21)(p13;q22) ( approximately 25%), or a high hyperdiploid (HeH) karyotype (30%). The t(12;21) translocation leads to the expression of a novel fusion gene, TEL-AML1 (ETV6-RUNX1), and HeH often involves tri- and tetrasomy for chromosome 21. The presence of TEL-AML1+ and HeH cells in utero prior to the development of leukaemia suggests that these lesions play a critical role in ALL initiation. Based on our previous analysis of HLA-DP in childhood ALL, and evidence from in vitro studies that TEL-AML1 can activate HLA-DP-restricted T cell responses, we hypothesised that the development of TEL-AML1+ ALL might be influenced by the child's DPB1 genotype. To test this, we analysed the frequency of six HLA-DPB1 supertypes in a population-based series of childhood leukaemias (n = 776) classified by their karyotype (TEL-AML1+, HeH and others), in comparison with newborn controls (n = 864). One DPB1 supertype (GKD) conferred significant protection against TEL-AML1+ ALL (odds ratio (OR), 95% confidence interval (95% CI): 0.42, 0.22-0.81; p < 0.005) and HeH ALL (OR; 95% CI: 0.44, 0.30-0.65; p < 0.0001). These negative associations were almost entirely due to a single allele, DPB1*0101. Our results suggest that DPB1*0101 may afford protection from the development of TEL-AML1+ and HeH BCP ALL, possibly as the result of a DP-restricted immune response to BCP ALL-associated antigen(s), the identification of which could have important implications for the design of prophylactic vaccines.
CitationHLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. 2008, 57 (1):53-61 Cancer Immunol. Immunother.
JournalCancer Immunology, Immunotherapy
- Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
- Authors: Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R
- Issue date: 2005 Apr 15
- Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.
- Authors: Peter A, Heiden T, Taube T, Körner G, Seeger K
- Issue date: 2009 Nov
- Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia.
- Authors: Gandemer V, Rio AG, de Tayrac M, Sibut V, Mottier S, Ly Sunnaram B, Henry C, Monnier A, Berthou C, Le Gall E, Le Treut A, Schmitt C, Le Gall JY, Mosser J, Galibert MD
- Issue date: 2007 Oct 23
- Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value.
- Authors: Codrington R, O'Connor HE, Jalali GR, Carrara P, Papaioannou M, Hart SM, Hoffbrand AV, Potter M, Prentice HG, Harrison CJ, Foroni L
- Issue date: 2000 Dec
- Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia.
- Authors: Martínez-Ramírez A, Urioste M, Contra T, Cantalejo A, Tavares A, Portero JA, López-Ibor B, Bernacer M, Soto C, Cigudosa JC, Benítez J
- Issue date: 2001 Dec